newsfilter
← Earnings
Earnings Releases·

Citius Oncology — Fiscal Fourth Quarter 2026 Earnings Summary

Citius Oncology reported a 120% increase in LYMPHIR unit sales to U.S. wholesalers during the fiscal fourth quarter of 2026, with 792 units purchased compared to 360 in the prior quarter. Prescribing centers ordered 950 vials during the period, bringing the total number of institutions that have ordered the drug to 54 as of late October 2026. The company aims to have LYMPHIR on formulary at 100 priority institutions by the end of the calendar year and expects continued growth as the therapy gains traction in treating cutaneous T-cell lymphoma.

Company
CITIUS PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology